Exacerbation of Bloody Diarrhea as a Side Effect of Mesalamine Treatment of Active Ulcerative Colitis
Authors:
Open Access
- 1 January 2011
- journal article
- Published by S. Karger AG in Case Reports in Gastroenterology
- Vol. 5 (1) , 159-165
Abstract
Mesalamine has been used as the first-line therapy for the treatment of ulcerative colitis (UC) because of its efficacy and fewer side effects. However, earlier study showed that mesalamine occasionally causes diarrhea. We are presenting a patient with active UC in whom bloody diarrhea accompanied by abdominal pain and fever occurred and the symptoms were aggravated after administration of mesalamine. In order to clarify the reason of symptoms aggravation, drug lymphocyte stimulation test and rechallenge trial with mesalamine were performed. The results indicated the possibility that aggravation was related to allergic reaction and was dose-dependent. Furthermore, we examined colonoscopic views but there was no remarkable change in before and after rechallenge trial. Based on the above result, the patient was diagnosed with mesalamine intolerance. In order to differentiate whether the exacerbation of bloody diarrhea is due to the side effects of the mesalamine or a true relapse of UC, taking careful history before and after increasing mesalamine dosage as well as being aware of side effects of mesalamine are required. Clinicians should be aware of diarrhea as a side effect of mesalamine particularly after onset of mesalamine formulation, change in mesalamine formulation, or change in mesalamine dose.Keywords
This publication has 16 references indexed in Scilit:
- Diarrhea as a Side Effect of Mesalamine Treatment for Inflammatory Bowel DiseaseJournal of Clinical Gastroenterology, 2000
- Adverse events in patients treated with 5‐aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in FranceAlimentary Pharmacology & Therapeutics, 1996
- Mesalazine induced exacerbation of ulcerative colitis.Gut, 1995
- Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitisDigestive Diseases and Sciences, 1995
- Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPaseJournal of Molecular Medicine, 1993
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Kinetics of 5‐aminosalicylic acid after jejunal instillation in man.British Journal of Clinical Pharmacology, 1983
- AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINEThe Lancet, 1977
- A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)Gut, 1973
- Controlled trial of sulphasalazine in the treatment of ulcerative colitisGut, 1964